It is currently Sat Sep 20, 2014 5:08 pm

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Gilenya doesn't stop post Tysabri reactivation

Taking Gilenya after stopping Tysabri doesn't suppress MS reactivation
http://www.overcomingmultiplesclerosis. ... ctivation/
Read more : Gilenya doesn't stop post Tysabri reactivation | Views : 1101 | Replies : 5


PMLCases now reach 331

As of Feb 05, the new total of PML cases has increased by 8, making the new total 331. Don't know if any more deaths are involved in the additional 8 cases.

http://chefarztfrau.de/?page_id=716

Harry
Read more : PMLCases now reach 331 | Views : 975 | Replies : 1


An assay to quantify species-specific anti-JC virus antibody

An assay to quantify species-specific anti-JC virus antibody levels in MS patients

Summary: This study looked at developing an assay for the reliable quantification of highly species-specific anti-JCV antibody levels and to compare the results with pre-existing data from the StratifyJCV® test.

The researchers tested the sera of 175 MS patients and matched non-MS-controls for anti-JCV antibodies using glutathione S-transferase-tagged-VP1 as antigen. In order to minimise the cross-reactivity between shared epitopes of JCV-VP1 and BKV-VP1, ...
Read more : An assay to quantify species-specific anti-JC virus antibody | Views : 1016 | Replies : 0


Tysabri may be an option for children with MS

Tysabri may be an option for children with Multiple Sclerosis

Off-label treatment with natalizumab (Tysabri) for 20 children with severe multiple sclerosis reduced relapses and brain lesions seen on MRI scans, a retrospective analysis found.

The mean annualized relapse rate while on natalizumab in these patients was 0.4, compared with 3.77 before starting the drug (P<0.001), according to Barbara Kornek, MD, of Austria's Medical University of Vienna, and colleagues.

Also, new T2/fluid attenuated inversion recovery ...
Read more : Tysabri may be an option for children with MS | Views : 636 | Replies : 0


Natalizumab in pediatric multiple sclerosis

Natalizumab in paediatric multiple sclerosis: results of a cohort of 55 cases

Abstract

BACKGROUND: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients.

OBJECTIVE: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients.

METHODS: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a ...
Read more : Natalizumab in pediatric multiple sclerosis | Views : 1047 | Replies : 0


MS Patient dies from anti-Tysabri antibodies

Svenningsson and colleagues concluded that her death resulted from "rebound neuroinflammation as a result of the development of natalizumab anti-drug antibodies."

Noteworthy was that the patient had shown unusual reactions to the drug starting with the fourth infusion, including chills and fever, they suggested.

"We recommend that repeated moderate to severe infusion reactions in the beginning of natalizumab treatment should prompt the cessation of treatment and assessment for the development of natalizumab anti-drug antibodies," Svenningsson ...
Read more : MS Patient dies from anti-Tysabri antibodies | Views : 1004 | Replies : 0


MS-UK Tysabri User Diaries

MS-UK Tysabri Diary Update

Kirsty has kindly sent in her 25th Tysabri Infusion Diary update.

You can read it at http://www.ms-uk.org/index.cfm/kirsty
Read more : MS-UK Tysabri User Diaries | Views : 1659 | Replies : 9


Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

Biogen Idec Inc. agreed to acquire partner Elan Corp.’s stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties.

The deal gives Biogen all rights to the product, and the company will pay royalties to Elan, Dublin-based Elan said in a statement today. The companies had been splitting profit equally on the medicine, which generated $1.6 billion in sales in 2012.

The deal ends speculation that Biogen would buy Elan ...
Read more : Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights | Views : 905 | Replies : 3


PML info in regards to MS treatment

http://www.ccjm.org/content/78/Suppl_2/S33.full

A bit of info regarding PML and how it relates to MS patients on Tysabri. It may all be well know, but5 it answered a few of my own questions so I thought I would share.
Read more : PML info in regards to MS treatment | Views : 1334 | Replies : 7


First-line use of Tysabri in anti-JCV antibody negative pts

Applications for first-line use of Tysabri in anti-JCV antibody negative patients with MS announced

Image

Biogen Idec and Elan Corporation, plc have announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the Tysabri® (natalizumab) labels. The applications request an expanded indication that would include first-line use for people living with certain relapsing forms of multiple sclerosis (MS) who have tested negative for ...
Read more : First-line use of Tysabri in anti-JCV antibody negative pts | Views : 1102 | Replies : 2


 

Login  •  Register


Statistics

Total posts 220051 • Total topics 22752 • Total members 14360


Contact us | Terms of Service